RIGL — Rigel Pharmaceuticals, Inc.

Summary of Rigel Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Net Product Sales: $65.4 million, a 41% increase year-over-year.
  • TAVALISSE: $45.6 million (up 47% YoY).
  • GAVRETO: $10.2 million (up 27% YoY).
  • REZLIDHIA: $9.6 million (up 29% YoY).
• Total Revenue: $69.8 million for Q4, including $4.4 million from collaborations.
• Full Year 2025 Net Income: $367 million, significantly up from $17.5 million in 2024.
• Cash Position: Ended 2025 with $155 million in cash and equivalents, up from $77.3 million in 2024.

2. Strategic Updates and Business Highlights

• Rigel has transformed from a single-product company in 2020 to a profitable entity with three commercial products and a robust pipeline.
• Strategic Objectives: Focus on growing the commercial business, expanding the portfolio through in-licensing, advancing the clinical pipeline (notably R289 for lower-risk MDS), and maintaining financial discipline.
• R289: A dual IRAK1/4 inhibitor showing promising results in a Phase Ib study for lower-risk MDS, with plans to expand into less heavily pretreated patients.
• Rigel has successfully integrated GAVRETO and REZLIDHIA into its portfolio, contributing to profitability.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenue of $275 million to $290 million, with net product sales projected at $255 million to $265 million.
• Anticipates continued positive net income while funding existing and new clinical development programs.
• Focus on sustaining double-digit growth, although not at the same rate as 2025 due to the absence of one-time favorable effects experienced last year.

4. Bad News, Challenges, or Points of Concern

• The growth in 2025 was partially driven by a one-time favorable effect from improved patient affordability, which is not expected to recur in 2026.
• Competitive pressures exist in the market, particularly for TAVALISSE, which may face challenges in maintaining growth as it matures.
• There are concerns regarding the ability to access clinicians effectively, which could hinder sales efforts.

5. Notable Q&A Insights

• On TAVALISSE Growth: Future growth will rely on increasing new patient starts, as the product matures and the one-time affordability boost will not repeat.
• On GAVRETO: The company is optimistic about growth opportunities despite not having the advantage of a full year of sales as in 2025.
• On R289 Dosing: The decision between 500 mg QD vs. BID will depend on ongoing data; both dosing regimens are being evaluated.
• On Business Development: Rigel is actively exploring late-stage opportunities in hematology/oncology but does not have a specific timeline for new acquisitions.
• On Enrollment for R289: Enrollment in the dose expansion phase is progressing, with plans to meet with regulators after sufficient follow-up data is collected.

Overall, Rigel Pharmaceuticals demonstrated strong financial performance in 2025, with a clear strategy for future growth, though it faces challenges related to market dynamics and competitive pressures.